Charles is a Research Analyst at Vestal Point, primarily covering pre-commercial stage therapeutics. Before Vestal Point, Charles was an Analyst working alongside Ryan Wilder at Point72 from 2017 to 2023 focusing on pre-commercial biotechnology stocks.
Ilko serves as Partner, COO, and CCO at Vestal Point, overseeing non-investment operations. Previously, he was Partner and COO at Pharo Management, an emerging markets macro hedge fund, from 2004 to 2023.
Marc leads trading at Vestal Point. Before joining, he was Head of ECM and Trading at Pinz Capital and previously managed a $50 million trading book at Centenus Capital while heading its Best Execution Committee.
The company invests in opportunities identified through proprietary insights into scientific or financial fundamentals, aiming for consistent excess returns through a disciplined process.
Vestal Point Capital specializes in life sciences investments, managing securities in biotechnology, pharmaceuticals, medical devices, tools, and diagnostics.
Vestal Point Capital specializes in life sciences investments, managing securities in biotechnology, pharmaceuticals, medical devices, tools, and diagnostics.
